Dose-Escalation Study of the Safety and Immunogenicity of a Novel Rabies Vaccine ChAd155-RG vs. the Comparator RABAVERT Vaccine in Healthy Adult Subjects
Conditions: Rabies; Rabies Immunisation Interventions: Biological: ChAd155-RG; Other: Placebo; Biological: Rabies Vaccine Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Allergy | Allergy & Immunology | Infectious Diseases | Rabies | Research | Study | Vaccines